OBJECTIVE: Tumor markers with increased sensitivity and specificity for endometrial cancer
are needed to help monitor response to therapy and to detect recurrent disease. Currently …

OBJECTIVE: To evaluate the prognostic value of pretherapeutic serum HE4 in endometrial
cancer in comparison to CA125. METHODS: HE4 and CA125 serum levels were analyzed …

Simple Summary There are currently no blood biomarkers approved for routine clinical use
in endometrial cancer. Serum human epididymis protein 4 (HE4) is significantly higher in …

Objective HE4 has emerged as a promising biomarker in gynaecological oncology. The
purpose of this study was to evaluate serum HE4 as a biomarker for high-risk phenotypes in …

The aim of the study was to explore the clinical value of serum human epididymis secretory
protein E4 (HE4) and CA125 in endometrial carcinoma. From January 2010 to April 2012 …

OBJECTIVE: To evaluate the utility of serum (HE4) as a marker for high risk disease in
patients with endometrial cancer (EC). METHODS: Preoperative serum HE4 levels were …

Background: To date, no good marker for screening or disease monitoring of endometrial
cancer (EC) is available. The aims of this study were to investigate HE4 gene, protein …

Background: The purpose of this study was to assess the diagnostic and prognostic impact
of preoperative serum determination of human epididymis protein 4 (sHE4), and to …

Purpose: Serum markers with increased sensitivity and specificity for endometrial cancer are
required. To date, no good marker has met this standard. The aims of our study were to …

Objective: The purpose of this pilot study was to determine whether the biomarker human
epididymis protein 4 (HE4) correlates with depth of myometrial invasion, histologic grade …